중증근무력증 치료 시장 : 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰, 예측(2026-2034년)

Growth Factors of myasthenia gravis treatment Market

The global myasthenia gravis treatment market was valued at USD 1.62 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, reaching USD 3.21 billion by 2034, exhibiting a CAGR of 7.89% during the forecast period (2026-2034). North America dominated the market with a 49.25% share in 2025, driven by strong healthcare infrastructure, high disease awareness, and access to advanced therapies.

Myasthenia gravis (MG) is a rare autoimmune disorder characterized by muscle weakness caused by disrupted nerve-muscle communication. Increasing prevalence, especially among the aging population, is significantly contributing to market expansion.

Market Trends

A key trend shaping the market is the growing shift toward novel and targeted therapies. Conventional treatments often cause side effects, encouraging patients and healthcare providers to adopt advanced biologics and monoclonal antibodies.

Pharmaceutical companies are investing heavily in R&D to introduce innovative drugs. For instance, therapies such as efgartigimod and monoclonal antibodies are gaining traction due to improved efficacy and safety profiles. Additionally, subcutaneous immunoglobulin (SCIg) therapies are emerging, supporting home-based care and improving patient convenience.

Market Growth Factors

Rising Disease Prevalence

The increasing global prevalence of MG is a major growth driver. Studies estimate over 700,000 patients worldwide, with 36,000-60,000 cases in the U.S. alone. Improved diagnostic capabilities and awareness campaigns are further boosting treatment demand.

Aging Population

The condition is more common among older adults, and with the global geriatric population rising, the demand for effective treatments is increasing. Higher life expectancy is directly contributing to higher disease incidence rates.

Strong Pipeline and Drug Approvals

Leading companies such as Argenx, CSL Behring, and F. Hoffmann-La Roche Ltd. are actively developing advanced therapies. Increasing approvals from regulatory authorities are accelerating market growth.

Restraining Factors

Despite positive growth, the market faces certain challenges:

• High Treatment Costs: Treatment expenses can be significantly higher compared to other chronic diseases, limiting accessibility.
• Limited Reimbursement in Developing Regions: Inadequate insurance coverage increases out-of-pocket expenses.
• Healthcare Infrastructure Gaps: Emerging economies still face challenges in diagnosis and treatment access.

These factors may hinder market expansion, particularly in low- and middle-income countries.

Segmentation Analysis

By Drug Class

The market is segmented into cholinesterase inhibitors, corticosteroids, immunosuppressants, IVIg, and others.

• The IVIg segment dominated with a 77.18% share in 2026, owing to its effectiveness in long-term treatment and fewer side effects.
• The monoclonal antibodies segment is expected to witness significant growth due to increasing demand for targeted therapies.

By Distribution Channel

• Hospital pharmacies held the largest share (45.36% in 2026), driven by higher hospitalization rates and physician supervision requirements.
• Online pharmacies are projected to grow at the fastest rate due to increasing digital adoption and convenience.

Regional Insights

North America

North America led the market with USD 0.8 billion in 2025, growing to USD 0.86 billion in 2026. Growth is supported by high disease prevalence, advanced healthcare systems, and favorable reimbursement policies.

Europe

Europe accounted for USD 0.45 billion in 2025 and is projected to reach USD 0.48 billion in 2026. Increasing funding for rare disease research and rising awareness are key growth drivers.

Asia Pacific

The region generated USD 0.23 billion in 2025 and is expected to reach USD 0.25 billion in 2026. It is projected to grow at the highest CAGR due to improving healthcare infrastructure and rising diagnosis rates.

Rest of the World

Regions such as Latin America and the Middle East are witnessing gradual growth due to increasing awareness and expanding healthcare access.

Key Industry Players

Major companies operating in the market include:

• AstraZeneca
• Astellas Pharma Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bausch Health Companies Inc.

These players focus on strategic collaborations, acquisitions, and product innovation to strengthen their market position.

Key Industry Developments

• 2023: UCB S.A. received FDA approval for ZILBRYSQ for generalized MG.
• 2023: AstraZeneca's Soliris approved in Japan for pediatric MG treatment.
• 2021: Argenx filed for FDA approval of efgartigimod.
• Ongoing partnerships and clinical trials are accelerating innovation in the market.

Conclusion

The global myasthenia gravis treatment market is poised for steady growth from USD 1.62 billion in 2025 to USD 3.21 billion by 2034, driven by rising disease prevalence, increasing awareness, and advancements in novel therapies. While high treatment costs and limited reimbursement remain key challenges, continuous R&D investments and the introduction of targeted biologics are expected to transform the treatment landscape. Overall, the market presents strong growth opportunities, particularly with the shift toward personalized medicine and improved healthcare access worldwide.

Segmentation By Drug Class

• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• IVIg
• Monoclonal Antibodies

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America (By Drug Class, By Distribution Channel, and By Country)
  • U.S. (By Drug Class)
  • Canada (By Drug Class)
• Europe (By Drug Class, By Distribution Channel, and By Country/Sub-region)
  • U.K. (By Drug Class)
  • Germany (By Drug Class)
  • France (By Drug Class)
  • Italy (By Drug Class)
  • Spain (By Drug Class)
  • Scandinavia (By Drug Class)
  • Rest of Europe (By Drug Class)
• Asia Pacific (By Drug Class, By Distribution Channel, and By Country/Sub-region)
  • Japan (By Drug Class)
  • India (By Drug Class)
  • China (By Drug Class)
  • Australia (By Drug Class)
  • Rest of Asia Pacific (By Drug Class)
• Rest of the World (By Drug Class, By Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Key Industry Developments (Mergers, Acquisitions, and Partnership)
• 4.2. New Product Launches, by Key Players
• 4.3. Impact of COVID-19 on the Market

5. Global Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Cholinesterase Inhibitors
  • 5.1.2. Corticosteroids
  • 5.1.3. Immunosuppressants
  • 5.1.4. IVIg
  • 5.1.5. Monoclonal Antibodies
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital Pharmacies
  • 5.2.2. Online Pharmacies
  • 5.2.3. Retail Pharmacies
• 5.3. Market Analysis, Insights and Forecast - By Geography
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Rest of World

6. North America Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Cholinesterase Inhibitors
  • 6.1.2. Corticosteroids
  • 6.1.3. Immunosuppressants
  • 6.1.4. IVIg
  • 6.1.5. Monoclonal Antibodies
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital Pharmacies
  • 6.2.2. Online Pharmacies
  • 6.2.3. Retail Pharmacies
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
    • 6.3.1.1. By Drug Class
  • 6.3.2. Canada
    • 6.3.2.1. By Drug Class

7. Europe Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Cholinesterase Inhibitors
  • 7.1.2. Corticosteroids
  • 7.1.3. Immunosuppressants
  • 7.1.4. IVIg
  • 7.1.5. Monoclonal Antibodies
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Online Pharmacies
  • 7.2.3. Retail Pharmacies
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.3.1. U.K.
    • 7.3.1.1. By Drug Class
  • 7.3.2. Germany
    • 7.3.2.1. By Drug Class
  • 7.3.3. France
    • 7.3.3.1. By Drug Class
  • 7.3.4. Spain
    • 7.3.4.1. By Drug Class
  • 7.3.5. Italy
    • 7.3.5.1. By Drug Class
  • 7.3.6. Scandinavia
    • 7.3.6.1. By Drug Class
  • 7.3.7. Rest of Europe
    • 7.3.7.1. By Drug Class

8. Asia Pacific Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Cholinesterase Inhibitors
  • 8.1.2. Corticosteroids
  • 8.1.3. Immunosuppressants
  • 8.1.4. IVIg
  • 8.1.5. Monoclonal Antibodies
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Online Pharmacies
  • 8.2.3. Retail Pharmacies
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.3.1. Japan
    • 8.3.1.1. By Drug Class
  • 8.3.2. China
    • 8.3.2.1. By Drug Class
  • 8.3.3. India
    • 8.3.3.1. By Drug Class
  • 8.3.4. Australia
    • 8.3.4.1. By Drug Class
  • 8.3.5. Rest of Asia Pacific
    • 8.3.5.1. By Drug Class

9. Rest of World Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Cholinesterase Inhibitors
  • 9.1.2. Corticosteroids
  • 9.1.3. Immunosuppressants
  • 9.1.4. IVIg
  • 9.1.5. Monoclonal Antibodies
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital Pharmacies
  • 9.2.2. Online Pharmacies
  • 9.2.3. Retail Pharmacies

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. AstraZeneca
    • 10.2.1.1. Overview
    • 10.2.1.2. Products & Services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Astellas Pharma Inc.
    • 10.2.2.1. Overview
    • 10.2.2.2. Products & Services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. F. Hoffmann-La Roche Ltd.
    • 10.2.3.1. Overview
    • 10.2.3.2. Products & Services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Novartis AG
    • 10.2.4.1. Overview
    • 10.2.4.2. Products & Services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Veloxis Pharmaceuticals, Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products & Services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Bausch Health Companies Inc.
    • 10.2.6.1. Overview
    • 10.2.6.2. Products & Services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)